7741 Participants Needed

aQIVc Vaccine for Flu in Adults 50+

Recruiting at 134 trial locations
CT
UC
Overseen ByUse Central Contact
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

What is the purpose of this trial?

This is a Phase 3, randomized, parallel-group, comparator-controlled, observer-blind, multicenter study of immunogenicity and safety in approximately 7700 male and female adults aged 50 years and older (approximately equally split between two age groups: 50-64 years; 65 years and older), who are healthy or have stable comorbidities that increase their risk of complications from influenza infection. Three lots of aQIVc will be evaluated for consistency and pooled for the comparison with the 2 control vaccines.Subjects will be randomly assigned to receive 1 of 3 lots of aQIVc, QIVr, or aQIV in a 1:1:1:2:2 ratio (for a 3:2:2 ratio for aQIVc, QIVr, and aQIV).The study will have a treatment period (Day 1 to Day 29) and a follow-up period (Day 30 up to Day 181); a subset of 770 subjects will be followed up up to Day 365.

Research Team

CP

Clinical Program Director

Principal Investigator

Seqirus

Eligibility Criteria

This trial is for adults aged 50 and older who are either healthy or have stable health issues that could make flu complications worse. They must be able to follow the study's procedures but can't join if they have immune problems, recent flu shots, Guillain-Barré syndrome, allergies to vaccine ingredients, or serious unstable conditions.

Inclusion Criteria

Individuals who can comply with all study procedures
I am 50 or older with stable health conditions that could worsen with the flu.

Exclusion Criteria

Known hypersensitivity or allergy to any study vaccine component
I have received the flu vaccine in the last 6 months.
My immune system is not working properly due to a condition or medication.
See 3 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive one of the influenza vaccines (aQIVc, QIVr, or aQIV) and are monitored for immunogenicity and safety

4 weeks
1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

22 weeks
Multiple visits (in-person and virtual)

Extended Follow-up

A subset of participants is monitored for long-term safety and immunogenicity

up to 52 weeks

Treatment Details

Interventions

  • aQIVc
Trial Overview The study tests three batches of a new flu vaccine called aQIVc against two existing vaccines (QIV1 and QIV2). Participants will be randomly assigned in specific ratios to receive one of these vaccines. The main goal is to compare how well each vaccine works and their safety over different periods up to one year.
Participant Groups
3Treatment groups
Experimental Treatment
Active Control
Group I: Investigational aQIVc groupExperimental Treatment1 Intervention
Group II: licensed aQIV groupActive Control1 Intervention
Group III: licensed QIVr groupActive Control1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Seqirus

Lead Sponsor

Trials
60
Recruited
1,081,000+

Dr. Paul McKenzie

Seqirus

Chief Executive Officer since 2023

PhD in Engineering

Dr. Gregg Sylvester

Seqirus

Chief Health Officer since 2016

MD from Albany Medical College, MPH from Johns Hopkins Bloomberg School of Public Health

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security